Inhibition of cardiac fibrosis by colchicine through differential increase in interleukin-10 and galectin-3 expression and decrease in the ratio of collagen I to collagen III and NT-proBNP in acute myocardial infarction (in vivo study on patients with acute myocardial infarction with ST-segment elevation undergoing primary and delayed percutaneous coronary intervention)

niversity of Brawijaya0 个研究点目标入组 200 人开始时间: 2024年1月2日最近更新: 2024年1月15日

适应症

试验速览

暂无简介。

•1. Patients diagnosed with STEMI for the first time, with the following diagnostic criteria: persistent typical chest pain >30 minutes lasting more than 12 hours, accompanied by ST-segment elevation in at least 2 contiguous leads, and an increase in cardiac enzymes, troponin I.
•2. Patients who have received information about the study and signed an informed consent.
•3. Patients not pregnant, breastfeeding, or planning pregnancy during the study period.
•4. Patients without a history of alcohol abuse.
•5. Patients not receiving long-term steroid therapy during the study.
•6. Patients not currently taking colchicine for other indications (e.g., gout arthritis, familial Mediterranean fever).

•1. Patients with poor medication adherence, as evidenced by the number of missed doses during the study.
•2. Patients with a history of hypersensitivity to colchicine.
•3. Patients with comorbidities such as infections, inflammation, malignancy, for instance, irritable bowel syndrome (Crohn's Disease or ulcerative colitis), severe renal failure (eGFR <30), a history of hepatic cirrhosis, acute exacerbation of hepatitis, or severe liver disease.
•4. Laboratory results as follows: Hemoglobin <11.5g/dl, Leukocytes < 3.0 x 10^9/L, Platelets < 110 x 10^9/L, ALT > 3 times the upper normal limit, Total Bilirubin > 2 times the upper normal limit, Creatinine > 2 times the upper normal limit.
•5. Patients who have experienced cardiac arrest.
•6. Patients with ventricular fibrillation.
•7. Patients with cardiogenic shock or unstable hemodynamics.

发起方

niversity of Brawijaya